Gewinn- und Verlustrechnung von Global Partners LP

Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR's $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value inflection points despite high R&D burn.

Eli Lilly's unapproved retatrutide is already popular, as evidenced by the black market for it. This underscores the strength of Eli Lilly's weight-loss pipeline.

NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.

BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual Commercial Strategy Day on Tuesday, September 1, 2026 at 11:00 AM ET to discuss the potential commercial opportunity and go-to-market strategy for Revita®.

Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluated avexitide – the pharmaceutical firm's first-in-class GLP-1 receptor antagonist – in patients suffering from post-bariatric hypoglycemia (PBH).

Amylyx Pharmaceuticals says its GLP-1 receptor antagonist, avexitide, met both the primary and secondary endpoints in a late-stage clinical trial.

Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.

Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 candidates in the pipeline.

Eli Lilly has faced spotty insurance coverage for its GLP-1 medicines in the weight-loss market. However, lower realized prices are driving substantially higher sales volume.

NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.